VANCOUVER, British Columbia, March 8, 2018 /CNW/ -- Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQX: LDSYF), (XETR:LD6) ("LDS" or the "Company") announces CSPA Group Inc. and LDS Scientific's launching of Rêveur, a new luxury brand of cannabis products for the California market.
The CSPA Group Inc. has been test marketing the core product in selected retail stores in California and the initial results have been very positive. The new product line Rêveur (the French word for Dreamer) will focus on the higher upscale luxury market using only fresh frozen organically grown cannabis strains processed at minus 50 degrees Celsius preserving all the natural terpenes and flavonoids. The Company has produced 15,000 grams of Rêveur Live Resin products in February. The Rêveur product launch will begin March 15 2018, with deliveries to strategically targeted retailers throughout California.
The product launch has been affected by the most recent testing requirements in California, which have created time delays in all accredited laboratories for the cannabis required testing. The new testing requirements are for concentrations of THC, THCA, CBD, CBDA CBN, CBG cannabinoids, twenty-two Terpenes, twenty residual solvents, herbicides and pesticides. The current timeline on a full spectrum laboratory result from a third-party accredited laboratory is running 10 to 15 business days. Brad Eckenweiler, CEO of LDS, stated, "In our manufacturing process we are now running four full spectrum testing protocols at four intervals in the process. First test prior to processing, second test on first pass extraction or crude product, third test upon distillation, and fourth test on the final product. We are confident that these protocols will benefit our customers and the industry." These new testing requirements have added additional time to production and additional cost, full spectrum test cost are running between $650 to $850 per laboratory sample. The results are critical at each level of testing to allow the material to continue in the manufacturing process, because as the material becomes more concentrated the results become more finite in ppm (parts per million), which may effect the suitability of the final product for the market place. The Company is looking forward to the larger market distribution of the Rêveur product line. The CannastripsTM product line has also been test marketing flavours for final formulation this month and based on those results the new formulation decisions will be announced and the much anticipated launch will be scheduled.
About Lifestyle Delivery Systems Inc. Lifestyle Delivery Systems Inc. is a licensed, state-compliant vertically integrated cannabis-related company. From our isogenic pollination nursery to our cutting edge, state-of-the-art production facility located in Southern California, LDS has become one of the most diverse, innovative and scientifically based cannabis companies throughout North America. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to smoking but also a new way to accurately meter the dosage and assure the purity of the product. From start to finish, the production process tests for quality and composition of all the ingredients used in each and every strip, resulting in a delivery system that is safe, consistent and effective.
On behalf of the board of directors of Lifestyle Delivery Systems Inc.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, The Company undertakes no obligation to publicly update or revise forward-looking information.